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Abstract: A novel series of (3-diethoxyphosphoryl)isoxazolidines substituted at C5 with
various quinazolinones have been synthesized by the 1,3-dipolar cycloaddition of N-methyl-C-
(diethoxyphosphoryl)nitrone with N3-substitued 2-vinyl-3H-quinazolin-4-ones. All isoxazolidines
were assessed for antiviral activity against a broad range of DNA and RNA viruses. Isoxazolidines
trans-11f/cis-11f (90:10), trans-11h and trans-11i/cis-11i (97:3) showed weak activity (EC50 = 6.84,
15.29 and 9.44 µM) toward VZV (TK+ strain) which was only one order of magnitude lower
than that of acyclovir used as a reference drug. Phosphonates trans-11b/cis-11b (90:10),
trans-11c, trans-11e/cis-11e (90:10) and trans-11g appeared slightly active toward cytomegalovirus
(EC50 = 27–45 µM). Compounds containing benzyl substituents at N3 in the quinazolinone skeleton
exhibited slight antiproliferative activity towards the tested immortalized cells with IC50 in the
21–102 µM range.
Keywords: phosphonate; isoxazolidine; quinazolinones; antiviral; cytostatic
1. Introduction
Nitrogen-containing heterocycles form the core of natural products (e.g., alkaloids) and they
are also present in many pharmacophores as well as in numerous marketed drugs. Among them,
quinazolines and quinazolinones have drawn special attention due to the broad spectrum of
biological activities of their derivatives, including sedative [1–3], anticancer [4–7], antiviral [8–12],
antibacterial [13–15], antifungal [15,16], anti-inflamatory [15,17–19] and antifibrotic [20,21] activities.
Several reviews focused on the synthetic strategies and biological activities of these compounds
have been published [22–29]. The significant impact of various functional groups installed into
quinazoline/quinazolinone frameworks on pharmacological properties have been proven.
In the last decades several compounds containing the quinazolin-4-one framework, which
exhibited promising anticancer as well as antiviral properties, have been obtained (Figure 1).
Furthermore, some biologically active substituted quinazolin-4(3H)-ones were isolated from various
fungi and bacteria species. For example, 2-(4-hydroxybenzyl)quinazolin-4(3H)-one (1) was
found in an entomopathogenic fungus Isaria farinosa and its strong inhibitory properties on the
replication of tobacco mosaic virus (TMV) [30] were recognised, whereas its 2-(4-hydroxybenzoyl)
analogue 2 present in fungus from Penicillium genus appeared only slightly active toward TMV [30].
Moreover, compound 1 exhibited significant cytotoxicity toward various cancer cell lines [31,32].
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Quinazolinone 3 isolated from Streptomyces sp. appeared cytotoxic against Vero cells [33]. Very recently
synthetic pyridine-containing analogue 4 and its 3-substituted derivatives 5 and 6 have been obtained
and their slight activity against influenza A virus was revealed [34]. On the other hand, various
2,3-disubstitued quinazolin-4(3H)-ones, including compounds 7–10, have been found to possess
antitumor activity [35].
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Figure 1. Examples of quinazolinones with antiviral and anticancer activity. 
In continuation of our studies on antiviral and cytostatic activity of isoxazolidine analogues of 
C-nucleoside analogues, we designed a new series of compounds of the general formula 11 
containing a substituted quinazolinone moiety as a false nucleobase at C5 in the isoxazolidine ring 
and the diethoxyphosphoryl function attached at C3. Our synthetic strategy to compounds  
trans-11/cis-11 relies on the 1,3-dipolar cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone 12 
[36] with 2-vinyl-3H-quinazolin-4-ones 13 substituted at N3 (Scheme 1). 
 
Scheme 1. Retrosynthesis of (isoxazolidinyl) phosphonates trans-11/cis-11. 
2. Results and Discussion 
2.1. Chemistry 
2-Vinyl-3H-quinazolin-4-ones 13 modified at N3 with substituted benzyl groups were 
synthesized from commercially available 2-aminobenzamide (14) by acylation with 3-chloro-
propionyl chloride followed by cyclization and dehydrohalogenation to prepare 2-vinyl-3H-
quinazolin-4-one (13a) as a key intermediate [37] and a subsequent reaction with substituted benzyl 
bromides 13b–i [38] (Scheme 2). Moreover, compounds 13j (R = Me) and 13k (R = Et) were also 
obtained with intention to determine the influence of the benzyl substituent on biological activity of 
the designed isoxazolidines trans-11/cis-11. In the 1H-NMR spectra of compounds 13a–k characteristic 
signals for vinyl protons were observed in the 6.94–5.59 ppm (three doublets of doublets). 
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In continuation of our studies on antiviral and cytostatic activity of isoxazolidine analogues
of C-nucleoside analogues, we designed a new series of compounds of the general formula 11
containing a substituted quinazolinone moiety as a false nucleobase at C5 in the isoxazolidine
ring and the diethoxyphosphoryl function attached at C3. Our synthetic strategy to compounds
trans-11/cis-11 relies on the 1,3-dipolar cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone
12 [36] with 2-vinyl-3H-quinazolin-4-ones 13 substituted at N3 (Scheme 1).
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Scheme 2. Synthesis of Compounds 13a–k. Reaction and conditions: a. 3-chloropropionyl chloride, 1,4-
dioxane, 0 °C; b. 5% NaOH-EtOH (2:1); c. RBr, KOH, CH3CN, 105 °C; d. MeI or EtI, KOH, CH3CN, 60 
°C. 
The 1,3-dipolar cycloaddition of a nitrone 12 with 2-vinylquinazolinones 13a–k led to the 
formation of diastereoisomeric mixtures of 5-substituted (3-diethoxyphosphoryl)isoxazolidines 
trans-11 and cis-11 with good (80%–88%) diastereoselectivities (Scheme 3, Table 1). Ratios of cis/trans 
diastereoisomers were calculated from 31P-NMR spectra of crude reaction mixtures and confirmed 
by the analysis of 1H-NMR spectral data. Crude mixtures of isoxazolidine cycloadducts were then 
subjected to purification on silica gel columns. However, attempts to isolate pure diastereoisomers 
were fruitful for trans-11a (R = H), trans-11c (R = 2-NO2-C6H4-CH2), trans-11g (R = 3-F-C6H4-CH2), 
trans-11h (R = 4-F-C6H4-CH2) and trans-11j (R = Me) only. 
 
Scheme 3. Synthesis of Isoxazolidines cis-11a–k and trans-11a–k. Reaction and conditions: a. toluene, 70 
°C, 24 h. 
Table 1. Isoxazolidines trans-11 and cis-11 obtained according to Scheme 3. 
Entry 
Quinazolinone 13 Ratio of  
Trans-11:Cis-11 
Yield (%) 
R 
a H 92:8 trans-11a (23) a + trans-11a and cis-11a (70) b
b C6H5-CH2 90:10 trans-11b and cis-11b (84) b 
c 2-NO2-C6H4-CH2 90:10 trans-11c (20) a + trans-11c and cis-11c (73) b
d 3-NO2-C6H4-CH2 92:8 trans-11d and cis-11d (98) b 
e 4-NO2-C6H4-CH2 90:10 trans-11e and cis-11e (91) b 
f 2-F-C6H4-CH2 90:10 trans-11f and cis-11f (94) b 
g 3-F-C6H4-CH2 90:10 trans-11g (7) a + trans-11g and cis-11g (89) b
h 4-F-C6H4-CH2 90:10 trans-11h (22) a + trans-11h and cis-11h (70) b
i 2,4-diF-C6H3-CH2 92:8 trans-11i and cis-11i (94) b 
j Me 94:6 trans-11j (19) a + trans-11j and cis-11j (78) b
k Et 92:8 trans-11k and cis-11k (86) b 
a yield of pure isomer; b yield of pure mixture of cis- and trans-isomers. 
The relative configurations of isoxazolidines trans-11a and cis-11a were established based on our 
previous studies on stereochemistry of cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone 
(12) with various vinyl aryls [39,40] since similar 1H-NMR spectral patters for the respective series of 
trans- and cis-isoxazolidines were observed. Since for compound trans-11a all necessary coupling 
constants were successfully extracted from the 1H- and 13C-NMR spectra, detailed conformational 
analysis was performed based on these data {J(H3-H4α) = 9.3 Hz [41], J(H3-H4β) = 8.3 Hz, J(H4α-P) = 9.9 Hz 
c . Synthesis of Compounds 13a–k. Reaction and conditions: a. 3-chlor ropionyl chloride,
1,4-dioxane, 0 ˝C; b. 5% NaOH-EtOH (2:1); c. RBr, KOH, CH3CN, 105 ˝C; d. MeI or EtI, KOH, CH3CN,
60 ˝C.
The 1,3-dipolar cycloaddition of a nitrone 12 with 2-vinylquinazolinones 13a–k led to the
formation of diastereoisomeric mixtures of 5-substituted (3-diethoxyphosphoryl)isoxazolidines trans-11
and cis-11 with good (80%–88%) diastereoselectivities (Scheme 3, Table 1). Ratios of cis/trans
diastereoisomers were calculated from 31P-NMR spectra of crude reaction mixtures and confirmed
by the analysis of 1H-NMR spectral data. Crude mixtures of isoxazolidine cycloadducts were then
subjected to purification on silica gel columns. However, attempts to isolate pure diastereoisomers
were fruitful for trans-11a (R = H), trans-11c (R = 2-NO2-C6H4-CH2), trans-11g (R = 3-F-C6H4-CH2),
trans-11h (R = 4-F-C6H4-CH2) and trans-11j (R = Me) only.
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Entry Quinazolinone 13 Ratio of
Trans-11:Cis-11
Yield (%)
R
a H 92:8 trans-11 (23) a + trans-11a and cis-11a (70) b
b C6H5-CH2 90:10 trans-11b and is-11b (84) b
c 2-NO2-C6H4- 2 90:10 trans-11c (20) a + trans-11c and cis-11c (73) b
d 3-NO2-C6H4-C 2 92:8 trans-11d and cis-11d (98) b
e 4-NO2- 6H4-CH2 90:10 trans-11e and cis-11e (91) b
f 2-F-C6H4-CH2 90:10 trans-11f and cis-11f (94) b
g 3-F-C6H4-CH2 90:10 trans-11g (7) a + trans-11g and cis-11g (89) b
h 4-F-C6H4-CH2 90:10 trans-11h (22) a + trans-11h and cis-11h (70) b
i 2,4-diF-C6H3-CH2 92:8 trans-11i and cis-11i (94) b
j Me 94:6 trans-11j (19) a + trans-11j and cis-11j (78) b
k Et 92:8 trans-11k and cis-11k (86) b
a yield of pure isomer; b yield of pure mixture of cis- and trans-isomers.
The relative configurations of isoxazolidines trans-11a and cis-11a were established based on our
previous studies on stereochemistry of cycloaddition of N-methyl-C-(diethoxyphosphoryl)nitrone (12)
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with various vinyl aryls [39,40] since similar 1H-NMR spectral patters for the respective series of trans-
and cis-isoxazolidines were observed. Since for compound trans-11a all necessary coupling constants
were successfully extracted from the 1H- and 13C-NMR spectra, detailed conformational analysis was
performed based on these data {J(H3-H4α) = 9.3 Hz [41], J(H3-H4β) = 8.3 Hz, J(H4α-P) = 9.9 Hz [42,43],
J(H4β-P) = 16.9 Hz, J(H4α-H5) = 6.2 Hz, J(H4β-H5) = 8.3 Hz, J(CCCP) = 8.5 Hz [44,45]} and revealed that
isoxazolidine ring in trans-11a adopts a 3E conformation in which the diethoxyphosphoryl group
resides in the equatorial position of the isoxazolidine ring while a quinazolinone substituent is located
pseudoequatorially (Figure 2). On the other hand, cis configuration of the minor isomer was established
from the corresponding couplings [J(H3-H4α) = 9.0 Hz, J(H3-H4β) = 6.5 Hz, J(H4α-P) = 11.2 Hz, J(H4β-P)
= 20.0 Hz, J(H4α-H5) = 9.1 Hz, J(H4β-H5) = 3.9 Hz, J(CCCP) = 7.3 Hz] indicating the 2E conformation of
the isoxazolidine ring (Figure 2). The additional arguments to support our assignments follow from
shielding of the CH3CH2OP protons observed for the cis isomer (∆δ ca. 0.1 ppm) when compared with
the trans-11a. Furthermore, it was found that on a 1H-NMR spectrum taken on the 83:17 mixture of
cis- and trans-11a, the H-N proton in the quinazolinone ring of cis-11a was significantly deshielded
(∆δ = 0.7 ppm) when compared with the trans isomer, highly likely, as a result of the hydrogen
bond formation with the phosphoryl oxygen amide, a phenomenon spatially achievable in the cis
isomer only.
Since introduction of various substituents at N3 of quinazolinone moiety has no influence on the
stereochemical outcome of the cycloaddition therefore configuration of the all major isoxazolidines 11
were assigned as trans, thereby minor ones as cis.
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Figure 2. The preferred conformations of trans-isoxazolidine trans-11a. 
2.2. Antiviral and Cytostatic Evaluation 
2.2.1. Antiviral Activity 
All obtained phosphonates trans-11a, trans-11c, trans-11g, trans-11h and trans-11j as well as 
mixtures of diastereoisomeric phosphonates trans-11b/cis-11b (90:10), trans-11d/cis-11d (90:10), trans-
11e/cis-11e (90:10), trans-11f/cis-11f (90:10), trans-11i/cis-11i (97:3) and trans-11k/cis-11k (97:3) were 
evaluated for inhibitory activity against a wide variety of DNA and RNA viruses, using the following 
cell-based assays: (a) human embryonic lung (HEL) cells: herpes simplex virus-1 (KOS), herpes 
simplex virus-2 (G), thymidine kinase deficient (acyclovir resistant) herpes simplex virus-1 (TK− KOS 
ACVr), vaccinia virus, adeno virus-2, vesicular stomatitis virus, cytomegalovirus (AD-169 strain -1 
and Davis strain), varicella-zoster virus (TK+ VZV Oka strain and TK− VZV 07-1 strain); (b) HeLa cell 
cultures: vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus; (c) Vero cell 
cultures: para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, 
yellow fever virus; (e) CRFK cell cultures: feline corona virus (FIPV) and feline herpes virus (FHV) 
and (d) MDCK cell cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus. 
Ganciclovir, cidofovir, acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, 
rimantadine, ribavirin, dextran sulfate (molecular weight 10,000, DS-10000), mycophenolic acid, 
Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used as the reference 
compounds. The antiviral activity was expressed as the EC50: the compound concentration required 
to reduce virus plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50% 
(other viruses). 
Several isoxazolidines trans-11/cis-11 were able to weakly inhibit the replication of TK+ and TK− 
VZV strains with EC50 values in the range of 6.84–100 μM (Table 2). Among them, phosphonates 
trans-11f/cis-11f (90:10) (R = 2-F-C6H4-CH2) (EC50 = 6.84 μM), trans-11h (R = 4-F-C6H4-CH2) (EC50 = 
15.29 μM), trans-11i/cis-11i (97:3) (R = 2,4-diF-C6H3-CH2) (EC50 = 9.44 μM) were the most active toward 
2.2. ntiviral and ytostatic Evaluation
, - , s- , tr s-11 - j
of diastereoisomeric phosphonates trans-11b/cis-11b (90:10), trans-11d/cis-11d (90:10),
trans-11e/cis-11e (90:10), trans-1 f/cis-1 f (90:10), trans-1 i/cis-11i (97:3) d trans-11k/cis-11k (97:3)
were evaluated for inhibitory activ ty against a wide variety of DNA and RNA viruses, using the
fo owing cell-based assays: (a) huma embryonic lung (HEL) cells: herp s simplex virus-1 (KOS),
her es simplex virus-2 (G), thymidine kinase deficient (acyclovir resistant) herpes simplex virus-1
(TK´ KOS ACVr), vaccinia virus, adeno v r s-2, vesicular stomatitis virus, cytomegalovirus (AD-169
strain -1 and Davis strain), varicella-zoster virus (TK+ VZV Oka strain and TK´ VZV 07-1 strain);
(b) HeLa c ll tures: vesicular stomatitis v rus, Coxsackie virus B4 and respir tory syn ytial virus;
(c) Vero cell cultures: para-infl enza-3 virus, reovirus-1, Sindbis virus, Coxsackie vir s B4, Punta Toro
virus, yellow fever virus; (e) CRFK cell cultures: feline corona virus (FIPV) a d f line he pes virus
(FHV) and (d) MDCK cell cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus.
, cidof vir, acyclovir, brivudin, zalcitabine, z namivir, alovudine, mantadine, ri antadi e,
bavirin, dextran sulfate (molecular weight 10,000, DS-10000), mycophenolic acid, Hippeastrum
hybrid agglutinin (HHA) and Urtica dioica agglutin n (UDA) were used as the reference compou ds.
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The antiviral activity was expressed as the EC50: the compound concentration required to reduce virus
plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50% (other viruses).
Several isoxazolidines trans-11/cis-11 were able to weakly inhibit the replication of TK+ and TK´
VZV strains with EC50 values in the range of 6.84–100 µM (Table 2). Among them, phosphonates
trans-11f/cis-11f (90:10) (R = 2-F-C6H4-CH2) (EC50 = 6.84 µM), trans-11h (R = 4-F-C6H4-CH2)
(EC50 = 15.29 µM), trans-11i/cis-11i (97:3) (R = 2,4-diF-C6H3-CH2) (EC50 = 9.44 µM) were the most
active toward TK+ VZV Oka strain, while exhibiting no activity toward TK´ VZV strain. The activity
of these isoxazolidines trans-11/cis-11 against TK+ VZV Oka strain was 8- to 22-folds lower than that
of the reference drug acyclovir.
Table 2. Cytotoxicity and antiviral activity against varicella-zoster virus (VZV) in HEL cell cultures.
Compound R
Antiviral Activity EC50 (µM) a Cytotoxicity (µM)
TK+ VZV Strain TK´ VZV Strain Cell Morphology MCC b
trans-11c 2-NO2-C6H4-CH2 46.47 100 >100
trans-11e/cis-11e (90:10) 4-NO2-C6H4-CH2 34.20 42.87 100
trans-11f/cis-11f (90:10) 2-F-C6H4-CH2 6.84 >20 100
trans-11h 4-F-C6H4-CH2 15.29 >20 100
trans-11i/cis-11i (97:3) 2,4-diF-C6H3-CH2 9.44 >20 100
trans-11k CH3CH2 38.80 41.57 >100
Acyclovir 0.71 39.69 >100
Brivudin 0.019 25.59 >100
a Effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 plaque
forming units (PFU); b Minimum cytotoxic concentration that causes a microscopically detectable alternation of
cell morphology.
On the other hand, the EC50 values for the TK´ VZV 07-1 strain (which is an acyclovir resistant
strain) of the phosphonates trans-11e/cis-11e (90:10) (R = 4-NO2-C6H4-CH2) (EC50 = 42.87 µM)
and trans-11k/cis-11k (97:3) (R = Et) (EC50 = 41.57 µM) were comparable to that of acyclovir
(EC50 = 39.69 µM). These derivatives showed similar EC50’s for TK+ and TK´ VZV strains and
therefore their potency against TK+ VZV was approximately 50-fold lower compared to acyclovir.
Furthermore, compounds trans-11b/cis-11b (90:10) (R = C6H5-CH2), trans-11c (R = 2-NO2-C6H4-
CH2), trans-11e/cis-11e (90:10) (R = 4-NO2-C6H4-CH2) and trans-11g (R = 3-F-C6H4-CH2) showed
some activity against human cytomegalovirus (EC50 = 27–45 µM), although they were less active
than ganciclovir and cidofovir used as the reference compounds (Table 3). None of the phosphonate
derivatives here described showed activity against the other tested DNA and RNA viruses.
Table 3. Antiviral activity and cytotoxicity against human cytomegalovirus in HEL cell cultures.
Compound R
Antiviral Activity EC50 (µM) a Cytotoxicity (µM)
AD-169 Strain Davis Strain Cell Morphology MCC b
trans-11b/cis-11b (90:10) C6H5-CH2 44.72 >20 ě100
trans-11c 2-NO2-C6H4-CH2 >100 44.72 ě20
trans-11e/cis-11e (90:10) 4-NO2-C6H4-CH2 44.72 20 >100
trans-11g 3-F-C6H4-CH2 >100 27.59 100
Ganciclovir 10.52 0.63 >350
Cidofovir 1.49 0.23 >300
a Effective concentration required to reduce virus plaque formation by 50%. Virus input was 100 plaque
forming units (PFU); b Minimum cytotoxic concentration that causes a microscopically detectable alternation of
cell morphology.
2.2.2. Cytostatic Activity
The 50% cytostatic inhibitory concentration (IC50) causing a 50% decrease in cell proliferation was
determined against murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa
and immortalized human dermal microvacsular endothelial cells (HMEC-1). Isoxazolidines trans-11a
(R = H) and trans-11j (R = Me) did not inhibit cell proliferation at the highest tested concentration
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(i.e., 250 µM), whereas trans-11k/cis-11k (97:3) (R = Et) appeared slightly cytostatic towards the tested
cell lines (IC50 = 85–101 µM). On the other hand (Table 4, entries b to i), compounds having benzyl
substituents at N3 in the quinazolinone moiety showed lower IC50 values (IC50 = 21–102 µM) thereby
indicating that installation of functionalized benzyl groups was profitable for inhibitory properties.
Table 4. Inhibitory effect of the tested compounds against the proliferation of murine leukemia (L1210),
human T-lymphocyte (CEM), human cervix carcinoma (HeLa) and immortalized human dermal
microvascular endothelial cells (HMEC-1).
Compound R
IC50 a (µM)
L1210 CEM HeLa HMEC-1
trans-11a H >250 >250 >250 >250
trans-11b/cis-11b (90:10) C6H5-CH2 49 ˘ 23 28 ˘ 4 82 ˘ 5 83 ˘ 16
trans-11c 2-NO2-C6H4-CH2 87 ˘ 22 76 ˘ 9 97 ˘ 0 92 ˘ 1
trans-11d/cis-11d (90:10) 3-NO2-C6H4-CH2 28 ˘ 11 21 ˘ 4 50 ˘ 4 58 ˘ 0
trans-11e/cis-11e (90:10) 4-NO2-C6H4-CH2 59 ˘ 32 34 ˘ 12 76 ˘ 4 102 ˘ 3
trans-11f/cis-11f (90:10) 2-F-C6H4-CH2 33 ˘ 7 29 ˘ 13 76 ˘ 11 77 ˘ 0
trans-11g 3-F-C6H4-CH2 35 ˘ 12 26 ˘ 6 62 ˘ 9 74 ˘ 3
trans-11h 4-F-C6H4-CH2 26 ˘ 1 30 ˘ 12 58 ˘ 5 78 ˘ 1
trans-11i/cis-11i (97:3) 2,4-diF-C6H3-CH2 26 ˘ 2 24 ˘ 8 55 ˘ 10 67 ˘ 4
trans-11j Me >250 >250 >250 >250
trans-11k/cis-11k (97:3) Et 101 ˘ 17 85 ˘ 13 97 ˘ 10 86 ˘ 11
5-Fluorouracil 0.33 ˘ 0.17 18 ˘ 5 0.54 ˘ 0.12 n.d.
a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%;
n.d.—not determined.
3. Experimental Section
3.1. General
1H-NMR spectra were taken in CDCl3 on the following spectrometers: Gemini 2000BB (200 MHz
Varian, Palo Alto, CA, USA), and Avance III (600 MHz, Bruker Instruments, Karlsruhe, Germany)
with TMS as internal standard. 13C-NMR spectra were recorded for CDCl3 solution on the
Bruker Avance III at 151.0 MHz. 31P-NMR spectra were performed in CDCl3 solution on the
Varian Gemini 2000 BB at 81.0 MHz or on Bruker Avance III at 243.0 MHz. IR spectra were
measured on an Infinity MI-60 FT-IR spectrometer (ATI Instruments North America-Mattson, Madison,
WI, USA). Melting points were determined on a Boetius apparatus (VEB Kombinat NAGEMA,
Dresden, Germany) and are uncorrected. Elemental analyses were performed by the Microanalytical
Laboratory of this Faculty on Perkin-Elmer PE 2400 CHNS analyzer (Perkin-Elmer Corp., Norwalk,
CT, USA). The following adsorbents were used: column chromatography, Merck silica gel 60
(70–230 mesh); analytical TLC, Merck (Merck KGaA, Darmstadt, Germany) TLC plastic sheets silica gel
60 F254. N-methyl-C-(diethoxyphosphoryl)nitrone (12) [36], 2-vinyl-3H-quinazolin-4-one (13a) [37] and
3-methyl-2-vinyl-3H-quinazolin-4-one (13j) [38] were obtained according to the literature procedures.
1H-, 13C- and 31P-NMR spectra of all new synthesised compounds are provided in Supplementary
Materials (Figures S1–S54).
3.2. General Procedure for the Synthesis of N3-Benzylated 2-Vinyl-3H-quinazolin-4-ones 13b–i
To the solution of 2-vinyl-3H-quinazolin-4-one (13a, 1.00 mmol) in acetonitrile (15 mL) potassium
carbonate (3.00 mmol) was added. After 15 min the respective benzyl bromide (1.10 mmol) was added
and the reaction mixture was stirred under reflux for 4 h. A solvent was removed and the residue
was extracted with water (3 ˆ 10 mL). An organic layer was dried (MgSO4), concentrated and the
crude product was purified on a silica gel column with a methylene chloride: hexane mixture (7:3, v/v)
followed by crystallisation (chloroform-petroleum ether) to give pure quinazolinones 13b–e and 13g–i.
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3-Benzyl-2-vinylquinazolin-4(3H)-one (13b). White amorphous solid, m.p. = 85 ˝C–87 ˝C
(reference [46]—colorless viscous oil). IR (KBr, cm´1) νmax: 3027, 2950, 2925, 1677, 1615, 1574, 1425,
1312, 1271, 952, 845, 778, 755, 585. 1H-NMR (200 MHz, CDCl3): δ = 8.20–8.19 (m, 1H), 7.92–7.88 (m,
1H), 7.83–7.78 (m, 1H), 7.58–7.49 (m, 3H), 7.46–7.36 (m, 3H), 6.94 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 1H,
CH=CH2), 6.73 (dd, 3J = 17.2 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.80 (dd, 3J = 10.1 Hz, 2J = 2.3 Hz, 1H,
CH=CH2), 5.69 (s, 2H, N-CH2). 13C-NMR (151 MHz, CDCl3): δ = 166.12 (s, C(O)), 159.97, 151.63, 137.17,
136.44, 133.57, 128.60, 128.28, 128.25, 127.67, 126.60, 123.81, 123.61, 115.59, 68.32 (s, N-CH2). Anal.
Calcd. for C17H14N2O: C, 77.84; H, 5.38; N, 10.68. Found: C, 77.69; H, 5.21; N, 10.88.
3-(2-Nitrobenzyl)-2-vinylquinazolin-4(3H)-one (13c). Yellowish amorphous solid, m.p. = 88 ˝C–91 ˝C.
IR (KBr, cm´1) νmax: 2952, 2851, 1615, 1574, 1525, 1493, 1396, 1312, 988, 1104, 988, 938, 780, 723, 664.
1H- NMR (600 MHz, CDCl3): δ = 8.24–8.22 (m, 1H), 8.18–8.16 (m, 1H), 7.96–7.94 (m, 1H), 7.87–7.82
(m, 2H), 7.69–7.67 (m, 1H), 7.59–7.53 (m, 2H), 6.91 (dd, 3J = 17.2 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 6.64
(dd, 3J = 17.2 Hz, 2J = 1.2 Hz, 1H, CH=CH2), 6.14 (s, 2H, N-CH2), 5.78 (dd, 3J = 10.4 Hz, 2J = 1.2 Hz,
1H, CH=CH2). 13C-NMR (151 MHz, CDCl3): δ = 165.51 (s, C(O)), 159.83, 151.80, 147.86, 136.77, 133.78,
133.65, 132.77, 129.02, 128.67, 128.86, 127.86, 126.85, 124.97, 124.12, 123.56, 123.26, 115.26, 64.79 (s,
N-CH2). Anal. Calcd. for C17H13N3O3: C, 66.44; H, 4.26; N, 13.67. Found: C, 66.23; H, 4.11; N, 13.38.
3-(3-Nitrobenzyl)-2-vinylquinazolin-4(3H)-one (13d). Yellowish amorphous solid, m.p. = 90 ˝C–93 ˝C.
IR (KBr, cm´1) νmax: 3093, 3020, 2958, 2941, 1615, 1574, 1562, 1523, 1345, 1044, 991, 965, 801, 764, 687.
1H-NMR (600 MHz, CDCl3): δ = 8.46 (brs, 1H), 8.25–8.23 (m, 1H), 8.22–8.20 (m, 1H), 7.94–7.89 (m,
2H), 7.86–7.83 (m, 1H), 7.63–7.60 (m, 1H), 7.57–7.55 (m, 1H), 6.94 (dd, 3J = 17.2 Hz, 3J = 10.4 Hz, 1H,
CH=CH2), 6.71 (dd, 3J = 17.2 Hz, 2J = 1.6 Hz, 1H, CH=CH2), 5.82 (dd, 3J = 10.4 Hz, 2J = 1.6 Hz, 1H,
CH=CH2), 5.80 (s, 2H, N-CH2). 13C-NMR (151 MHz, CDCl3): δ = 165.61 (s, C(O)), 159.72, 151.74,
148.48, 138.58, 136.98, 133.89, 133.82, 129.61, 127.82, 126.88, 123.89, 123.33, 123.15, 122.98, 115.24, 66.83
(s, N-CH2). Anal. Calcd. for C17H13N3O3: C, 66.44; H, 4.26; N, 13.67. Found: C, 66.12; H, 3.97; N, 13.40.
3-(4-Nitrobenzyl)-2-vinylquinazolin-4(3H)-one (13e). Yellowish amorphous solid, m.p. = 131 ˝C–132 ˝C.
IR (KBr, cm´1) νmax: 2944, 2849, 1608, 1570, 1514, 1488, 1338, 1162, 984, 854, 812, 704, 680. 1H-NMR
(600 MHz, CDCl3): δ = 8.30–8.28 (m, 2H), 8.24–8.21 (m, 1H), 7.96–7.94 (m, 1H), 7.87–7.84 (m, 1H),
7.73–7.72 (m, 2H), 7.58–7.55 (m, 1H), 6.93 (dd, 3J = 17.2 Hz, 3J = 10.4 Hz, 1H, CH=CH2), 6.68 (dd,
3J = 17.2 Hz, 2J = 1.8 Hz, 1H, CH=CH2), 5.82 (s, 2H, N-CH2), 5.80 (dd, 3J = 10.4 Hz, 2J = 1.6 Hz,
1H, CH=CH2). 13C-NMR (151 MHz, CDCl3): δ = 165.59 (s, C(O)), 159.74, 151.78, 147.77, 143.81,
136.97, 133.87, 128.31, 127.89, 126.91 123.91, 123.85, 123.27, 115.25, 66.78 (s, N-CH2). Anal. Calcd. for
C17H13N3O3: C, 66.44; H, 4.26; N, 13.67. Found: C, 66.23; H, 4.03; N, 13.33.
3-(2-Fluorobenzyl)-2-vinylquinazolin-4(3H)-one (13f). Colorless oil; IR (film, cm´1) νmax: 3061, 1676,
1618, 1496, 1422, 1349, 1104, 988, 941, 759, 680, 661. 1H-NMR (200 MHz, CDCl3): δ = 8.17–8.13 (m,
1H), 7.92–7.74 (m, 2H), 7.61–7.45 (m, 2H), 7.41–7.29 (m, 1H), 7.26–7.08 (m, 2H), 6.93 (dd, 3J = 17.2 Hz,
3J = 10.0 Hz, 1H, CH=CH2), 6.74 (dd, 3J = 17.2 Hz, 2J = 2.4 Hz, 1H, CH=CH2), 5.79 (dd, 3J = 10.0 Hz,
2J = 2.4 Hz, 1H, CH=CH2), 5.76 (s, 2H, N-CH2). 13C-NMR (151 MHz, CDCl3): δ = 165.95 (s, C(O)),
161.15 (d, 1J(CF) = 249.1 Hz, C2), 159.93, 151.69, 137.12, 133.57, 130.54 (d, 3J(CCCF) = 3.5 Hz, C4),
130.13 (d, 3J(CCCF) = 8.5 Hz, C6), 127.71, 126.61, 124.17 (d, 4J(CCCCF) = 3.4 Hz, C5), 123.85, 123.66 (d,
2J(CCF) = 14.4 Hz, C3), 123.56, 115.54 (d, 2J(CCF) = 21.1 Hz, C1), 115.51, 62.16 (d, 3J(CCCF) = 4.4 Hz,
N-CH2). Anal. Calcd. for C17H13FN2O: C, 72.85; H, 4.67; N, 9.99. Found: C, 72.78; H, 4.41; N, 9.80.
3-(3-Fluorobenzyl)-2-vinylquinazolin-4(3H)-one (13g). White amorphous solid, m.p. = 58 ˝C–59 ˝C.
IR (KBr, cm´1) νmax: 3095, 3057, 3032, 1618, 1578, 1498, 1422, 1349, 1106, 988, 945, 681, 520. 1H-NMR
(200 MHz, CDCl3): δ = 8.20–8.15 (m, 1H), 7.93–7.88 (m, 1H), 7.84–7.75 (m, 1H), 7.55–7.47 (m, 1H),
7.39–7.22 (m, 3H), 7.10–7.01 (m, 1H), 6.93 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 1H, CH=CH2), 6.70 (dd,
3J = 17.2 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.79 (dd, 3J = 10.1 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.67 (s, 2H,
N-CH2). 13C-NMR (151 MHz, CDCl3): δ = 165.88 (s, C(O)), 162.95 (d, 1J(CF) = 246.6 Hz, C3), 159.88,
151.69, 138.97 (d, 3J(CCCF) = 7.8 Hz, C5), 137.09, 133.67, 130.15 (d, 3J(CCCF) = 8.8 Hz, C1), 127.75, 126.72,
Molecules 2016, 21, 959 8 of 15
123.84, 123.53 (d, 4J(CCCCF) = 2.4 Hz, C6), 123.48, 115.45, 115.09 (d, 2J(CCF) = 21.0 Hz, C4), 114.93 (d,
2J(CCF) = 22.0 Hz, C2), 67.39 (s, N-CH2). Anal. Calcd. for C17H13FN2O: C, 72.85; H, 4.67; N, 9.99. Found:
C, 72.66; H, 4.38; N, 9.95.
3-(4-Fluorobenzyl)-2-vinylquinazolin-4(3H)-one (13h). White amorphous solid, m.p. = 125 ˝C–127 ˝C. IR
(KBr, cm´1) νmax: 3058, 1677, 1618, 1493, 1425, 1349, 1102, 992, 942, 757, 683, 658. 1H-NMR (200 MHz,
CDCl3): δ = 8.12–8.07 (m, 1H), 7.87–7.82 (m, 1H), 7.78–7.73 (m, 1H), 7.51–7.40 (m, 3H), 7.10–6.97
(m, 2H), 6.88 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 1H, CH=CH2), 6.66 (dd, 3J = 17.2 Hz, 2J = 2.3 Hz, 1H,
CH=CH2), 5.74 (dd, 3J = 10.1 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.59 (s, 2H, N-CH2). 13C-NMR (151 MHz,
CDCl3): δ = 165.99 (s, C(O)), 162.71 (d, 1J(CF) = 249.1 Hz, C4), 159.90, 151.69, 137.19, 133.59, 132.26 (d,
4J(CCCCF) = 3.2 Hz, C1), 130.22 (d, 3J(CCCF) = 7.7 Hz, C2, C6), 127.74, 126.62, 123.70, 123.49, 115.55 (d,
2J(CCF) = 21.3 Hz, C3, C5), 67.58 (s, N-CH2). Anal. Calcd. for C17H13FN2O: C, 72.85; H, 4.67; N, 9.99.
Found: C, 72.67; H, 4.30; N, 9.70.
3-(2,4-Difluorobenzyl)-2-vinylquinazolin-4(3H)-one (13i). Yellowish amorphous solid, m.p. = 67 ˝C–68 ˝C.
IR (KBr, cm´1) νmax: 3076, 3015, 2929, 1681, 1606, 1574, 1505, 1351, 1279, 1100, 964, 851, 772, 666, 683.
1H-NMR (200 MHz, CDCl3): δ = 8.10–8.05 (m, 1H), 7.86–7.82 (m, 1H), 7.78–7.68 (m, 1H), 7.57–7.40
(m, 2H), 6.90–6.78 (m, 2H), 6.88 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 1H, CH=CH2), 6.67 (dd, 3J = 17.2 Hz,
2J = 2.3 Hz, 1H, CH=CH2), 5.74 (dd, 3J = 10.1 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.65 (s, 2H, N-CH2).
13C-NMR (151 MHz, CDCl3): δ = 165.84 (s, C(O)), 163.11 (dd, 1J(CF) = 249.9 Hz, 3J(CCCF) = 12.1 Hz,
C2) 161.40 (dd, 1J(CF) = 251.2 Hz, 3J(CCCF) = 12.1 Hz, C4), 159.85, 151.69, 137.11, 133.64, 131.70 (dd,
3J(CCCF) = 9.8 Hz, 3J(CCCF) = 5.5 Hz, C6), 127.75, 126.66, 123.81, 123.46, 119.69 (dd, 2J(CCF) = 14.6 Hz,
4J(CCCCF) = 3.6 Hz, C1), 115.44, 111.40 (dd, 2J(CCF) = 21.0 Hz, 4J(CCCCF) = 3.4 Hz, C5), 104.07 (dd,
2J(CCF) = 25.3 Hz, 2J(CCF) = 25.0 Hz, C3), 61.61 (d, 3J(CCCF) = 4.0 Hz, N-CH2). Anal. Calcd. for
C17H12F2N2O: C, 68.45; H, 4.06; N, 9.39. Found: C, 68.19; H, 3.87; N, 9.45.
3.3. General Procedure for the Synthesis of N3-Alkylated 2-Vinyl-3H-quinazolin-4-ones 13j and 13k
To the solution of 2-vinyl-3H-quinazolin-4-one (13a, 1.00 mmol) in acetonitrile (15 mL) potassium
carbonate (3.00 mmol) was added. After 15 min. iodomethane (2.00 mmol) or iodoethane (1.10 mmol)
was added and the reaction mixture was stirred at 60 ˝C for 5 h. The solvent was removed and a
residue was extracted with water (3 ˆ 10 mL). Organic layer was dried (MgSO4), concentrated and the
crude product was purified on a silica gel column with methylene chloride:hexane mixture (7:3, v/v)
followed by crystallization (chloroform : petroleum ether) to give pure quinazolinones 13j [35] or 13k.
3-Methyl-2-vinylquinazolin-4(3H)-one (13j). Amorphous solid, m.p. = 122 ˝C–124 ˝C (reference [35]
m.p. = 123 ˝C–125 ˝C).
3-Ethyl-2-vinylquinazolin-4(3H)-one (13k). Yellowish oil; IR (film, cm´1) νmax: 3066, 2979, 2927, 2855,
1684, 1621, 1576, 1423, 1381, 1163, 962, 768, 681. 1H-NMR (200 MHz, CDCl3): δ = 8.16–8.11 (m, 1H),
7.90–7.85 (m, 1H), 7.81–7.73 (m, 1H), 7.52–7.44 (m, 1H), 6.91 (dd, 3J = 17.2 Hz, 3J = 10.1 Hz, 1H,
CH=CH2), 6.69 (dd, 3J = 17.2 Hz, 2J = 2.3 Hz, 1H, CH=CH2), 5.76 (dd, 3J = 10.1 Hz, 2J = 2.3 Hz, 1H,
CH=CH2), 4.68 (q, 3J = 7.1 Hz, 2H, CH2CH3), 1.52 (t, 3J = 7.1 Hz, 3H, CH2CH3). 13C-NMR (151 MHz,
CDCl3): δ = 166.31 (s, C(O)), 160.09, 151.51, 137.29, 133.35, 127.62, 126.39, 123.55, 115.66, 62.70 (s,
CH2CH3), 14.34 (s, CH2CH3). Anal. Calcd. for C12H12N2O ˆ 0.25 H2O: C, 70.40; H, 6.15; N, 13.68.
Found: C, 70.73; H, 5.92; N, 13.80.
3.4. General Procedure for the Synthesis of Isoxazolidines Trans-11 and Cis-11
A solution of the nitrone 12 (1.0 mmol) and the respective vinyl quinazolinone (1.0 mmol) in
toluene (2 mL) was stirred at 70 ˝C until the disappearance (TLC) of the starting nitrone. All volatiles
were removed in vacuo and crude products were subjected to chromatography on silica gel columns
with a chloroform/methanol (100:1, 50:1, 20:1, v/v) mixtures as eluents.
Diethyl trans-(2-methyl-5-(4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)phosphonate (trans-11a).
Yellowish oil; IR (film, cm´1) νmax: 3085, 2980, 2929, 2782, 1687, 1610, 1469, 1331, 1132, 1098, 1052,
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968, 775. 1H-NMR (600 MHz, CDCl3): δ = 10.13 (s, 1H, NH), 8.31–8.29 (m, 1H), 7.80–7.78 (m,
1H), 7.71–7.69 (m, 1H), 7.53–7.50 (m, 1H), 5.04 (dd, 3J(H5–H4β) = 8.3 Hz, 3J(H5–H4α) = 6.2 Hz, 1H,
HC5), 4.29–4.20 (m, 4H, 2 ˆ CH2OP), 3.28–3.24 (m, 1H, HC3), 3.13 (dddd, 3J(H4β–P) = 16.9 Hz,
2J(H4β–H4α) = 12.8 Hz, 3J(H4β–H3) = 8.3 Hz, 3J(H4β–H5) = 8.3 Hz, 1H, HβC4), 3.05 (s, 3H, CH3N), 2.96
(dddd, 2J(H4α–H4β) = 12.8 Hz, 3J(H4α–P) = 9.9 Hz, 3J(H4α–H3) = 9.3 Hz, 3J(H4α–H5) = 6.2 Hz, 1H, HαC4),
1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.38 (t, 3J = 7.2 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3):
δ = 161.75 (s, C(O)), 153.76, 148.61, 134.82, 127.45, 127.15, 126.60, 121.61, 75.82 (d, 3J(CCCP) = 8.5 Hz,
C5), 63.76 (d, 1J(CP) = 170.0 Hz, C3), 63.36 (d, 2J(COP) = 6.5 Hz, CH2OP), 62.59 (d, 2J(COP) = 7.3 Hz,
CH2OP), 46.33 (s, CH3N), 37.77 (d, 2J(CCP) = 1.9 Hz, C4), 16.53 (d, 3J(CCOP) = 5.7 Hz, CH3CH2OP),
16.46 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 20.64. Anal. Calcd. for
C16H22N3O5P ˆ 0.25 H2O: C, 51.68; H, 6.10; N, 11.30. Found: C, 51.63; H, 6.09; N, 11.32.
Diethyl cis-(2-methyl-5-(4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)phosphonate (cis-11a). Data noted
below correspond to a 17:83 mixture of trans-11a and cis-11a. Yellowish oil; IR (film, cm´1) νmax: 3202,
3086, 2980, 2926, 2791, 1688, 1610, 1567, 1469, 1392, 1330, 1231, 1163, 1100, 1024, 973, 776, 573. (signals of
cis-11a were extracted from the spectra of a 17:83 mixture of trans-11a and cis-11a); 1H-NMR (600 MHz,
CDCl3): δ = 10.48 (s, 1H, NH), 8.31–8.29 (m, 1H), 7.77–7.75 (m, 1H), 7.67–7.65 (m, 1H), 7.50–7.47 (m,
1H), 5.10 (dd, 3J(H5–H4α) = 9.1 Hz, 3J(H5–H4β) = 3.9 Hz, 1H, HC5), 4.27–4.11 (m, 4H, 2 ˆ CH2OP), 3.21
(dddd, 3J(H4α–P) = 11.2 Hz, 2J(H4β–H4α) = 12.6 Hz, 3J(H4α–H5) = 9.1 Hz, 3J(H4α–H3) = 9.0 Hz, 1H, HαC4),
3.10 (ddd, 3J(H3–H4α) = 9.0 Hz, 3J(H3–H4β) = 6.5 Hz, 2J(H3-P) = 3.9 Hz, 1H, HC3), 3.01 (s, 3H, CH3N), 2.85
(dddd, 3J(H4β–P) = 20.0 Hz, 2J(H4α–H4β) = 12.6 Hz, 3J(H4β–H3) = 6.5 Hz, 3J(H4β–H5) = 3.9 Hz, 1H, HβC4),
1.31 (t, 3J = 7.5 Hz, 3H, CH3CH2OP), 1.25 (t, 3J = 6.5 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3):
δ = 161.52 (s, C(O)), 156.11, 148.53, 134.53, 127.14, 126.88, 126.67, 121.83, 75.51 (d, 3J(CCCP) = 7.3 Hz,
C5), 63.66 (d, 1J(CP) = 168.5 Hz, C3), 63.23 (d, 2J(COP) = 6.6 Hz, CH2OP), 63.03 (d, 2J(COP) = 6.7 Hz,
CH2OP), 45.62 (d, 3J(CNCP) = 5.4 Hz, CH3N), 37.96 (s, C4), 16.38 (d, 3J(CCOP) = 5.5 Hz, CH3CH2OP),
16.35 (d, 3J(CCOP) = 5.5 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 20.87. Anal. Calcd. for
C16H22N3O5P ˆ 0.25 H2O: C, 51.68; H, 6.10; N, 11.30. Found: C, 51.63; H, 6.05; N, 11.32 (obtained on a
90:10 mixture of trans-11a and cis-11a).
Diethyl trans-(5-(3-benzyl-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)phosphonate
(trans-11b). Yellowish oil; IR (film, cm´1) νmax: 3065, 3033, 2981, 2915, 2779, 1687, 1620, 1574, 1498,
1455, 1347, 1239, 1104, 1026, 966, 774, 683. 1H-NMR (600 MHz, CDCl3): δ = 8.22–8.20 (m, 1H), 7.97–7.95
(m, 1H), 7.84–7.82 (m, 1H), 7.57–7.54 (m, 1H), 7.43–7.41 (m, 1H), 7.38–7.36 (m, 1H), 5.67 (s, 2H,
N-CH2), 5.28 (dd, 3J(H5–H4β) = 7.4 Hz, 3J(H5–H4α) = 6.5 Hz, 1H, HC5), 4.33–4.20 (m, 4H, 2 ˆ CH2OP),
3.45–3.42 (m, 1H, HC3), 3.06 (s, 3H, CH3N), 3.07–2.97 (m, 2H, HαC4, HβC4), 1.42 (t, 3J = 7.0 Hz,
3H, CH3CH2OP), 1.39 (t, 3J = 7.1 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ = 167.04 (s,
C(O)), 162.94, 151.27, 136.14, 133.71, 128.59, 128.30, 128.24, 127.86, 127.12, 123.50, 115.60, 80.30 (d,
3J(CCCP) = 8.6 Hz, C5), 68.73 (s, CH2N), 64.44 (d, 1J(CP) = 168.2 Hz, C3), 63.25 (d, 2J(COP) = 6.5 Hz,
CH2OP), 62.55 (d, 2J(COP) = 6.9 Hz, CH2OP), 46.63 (s, CH3N), 37.95 (s, C4), 16.56 (d, 3J(CCOP) = 5.6 Hz,
CH3CH2OP), 16.51 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.19. Anal.
Calcd. for C23H28N3O5P: C, 60.39; H, 6.17; N, 9.19. Found: C, 59.99; H, 6.21; N, 9.15.
Diethyl trans-(2-methyl-5-(3-(2-nitrobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)-phosphonate
(trans-11c). Yellowish oil; IR (film, cm´1) νmax: 3067, 2973, 2918, 1620, 1576, 1526, 1347, 1337,
1264, 1050, 1018, 964, 790, 733, 584, 571. 1H-NMR (200 MHz, CDCl3): δ = 8.18–8.07 (m,
2H), 7.93–7.69 (m, 3H), 7.60–7.42 (m, 3H), 6.01 (s, 2H, N-CH2), 5.15 (dd, 3J(H5–H4β) = 7.8 Hz,
3J(H5–H4α) = 6.1 Hz, 1H, HC5), 4.29–4.07 (m, 4H, 2 ˆ CH2OP), 3.28 (ddd, 3J(H3–H4α) = 10.6 Hz,
3J(H3–H4β) = 8.5 Hz, 2J(H3-P) = 1.2 Hz, 1H, HC3), 2.93 (s, 3H, CH3N), 2.99–2.82 (m, 1H, HβC4), 2.76
(dddd, 3J(H4α–P) = 12.5 Hz, 2J(H4α–H4β) = 12.5 Hz, 3J(H4α–H3) = 10.6 Hz, 3J(H4α–H5) = 6.1 Hz, 1H, HαC4),
1.33 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.31 (t, 3J = 7.0 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3):
δ = 166.51 (s, C(O)), 162.99, 151.40, 147.85, 133.98, 133.68, 132.46, 129.10, 128.82, 128.08, 127.44, 125.06,
123.19, 115.30, 80.23 (d, 3J(CCCP) = 8.4 Hz, C5), 65.34 (s, N-CH2), 64.33 (d, 1J(CP) = 168.4 Hz, C3), 63.19 (d,
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2J(COP) = 6.5 Hz, CH2OP), 62.44 (d, 2J(COP) = 7.1 Hz, CH2OP), 46.58 (d, 3J(CNCP) = 3.8 Hz, CH3N), 37.98
(s, C4), 16.55 (d, 3J(CCOP) = 6.4 Hz, CH3CH2OP), 16.49 (d, 3J(CCOP) = 5.7 Hz, CH3CH2OP). 31P-NMR
(81 MHz, CDCl3): δ = 22.85. Anal. Calcd. for C23H27N4O7P ˆ 0.25 H2O: C, 54.49; H, 5.47; N, 11.05.
Found: C, 54.42; H, 5.28; N, 10.89.
Diethyl trans-(2-methyl-5-(3-(3-nitrobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)-phosphonate
(trans-11d). Data noted below correspond to a 92:8 mixture of trans-11d and cis-11d. A yellowish oil;
IR (film, cm´1) νmax: 3070, 2982, 2930, 2910, 1620, 1574, 1531, 1497, 1415, 1298, 1103, 1025, 774, 733,
682. (signals of trans-11d were extracted from the spectra of a 92:8 mixture of trans-11d and cis-11d);
1H-NMR (600 MHz, CDCl3): δ = 8.46–8.44 (m, 1H), 8.25–8.22 (m, 2H), 8.00–7.98 (m, 1H), 7.91–7.88 (m,
2H), 7.63–7.60 (m, 2H), 5.78 (s, 2H, N-CH2), 5.28 (dd, 3J(H5–H4β) = 6.8 Hz, 3J(H5–H4α) = 6.8 Hz, 1H, HC5),
4.33–4.20 (m, 4H, 2 ˆ CH2OP), 3.40–3.38 (m, 1H, HC3), 3.07–3.00 (m, 1H, HβC4), 3.05 (s, 3H, CH3N),
2.98 (dddd, 3J(H4α–P) = 12.2 Hz, 2J(H4α–H4β) = 12.2 Hz, 3J (H4α–H3) = 9.8 Hz, 3J(H4α–H5) = 6.8 Hz, 1H,
HαC4), 1.42 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.40 (t, 3J = 6.7 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz,
CDCl3): δ = 166.54 (s, C(O)), 162.63, 151.38, 148.50, 138.29, 134.06, 133.97, 129.65, 128.02, 127.45, 123.25,
123.00, 115.30, 80.14 (d, 3J(CCCP) = 8.4 Hz, C5), 67.21 (s, N-CH2), 64.42 (d, 1J(CP) = 168.5 Hz, C3), 63.24 (d,
2J(COP) = 6.5 Hz, CH2OP), 62.44 (d, 2J(COP) = 7.2 Hz, CH2OP), 46.33 (s, CH3N), 37.84 (s, C4), 16.56 (d,
3J(CCOP) = 5.6 Hz, CH3CH2OP), 16.46 (d, 3J(CCOP) = 4.2 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3):
δ = 22.07. Anal. Calcd. for C23H27N4O7P: C, 54.98; H, 5.42; N, 11.15. Found: C, 54.62; H, 5.24; N, 11.14
(obtained on a 92:8 mixture of trans-11d and cis-11d).
Diethyl trans-(2-methyl-5-(3-(4-nitrobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)-phosphonate
(trans-11e). Data noted below correspond to a 90:10 mixture of trans-11e and cis-11e. A yellowish
oil; IR (film, cm´1) νmax: 3073, 2982, 2929, 2781, 1687, 1608, 1523, 1498, 1342, 1106, 968, 851, 739.
(signals of trans-11e were extracted from the spectra of a 90:10 mixture of trans-11e and cis-11e);
1H-NMR (600 MHz, CDCl3): δ = 8.29–8.27 (m, 2H), 8.23–8.21 (m, 1H), 8.00–7.98 (m, 1H), 7.89–7.86
(m, 1H), 7.72–7.70 (m, 2H), 7.62–7.60 (m, 1H), 5.77 (s, 2H, N-CH2), 5.26 (dd, 3J(H5–H4β) = 6.8 Hz,
3J(H5–H4α) = 6.8 Hz, 1H, HC5), 4.33–4.19 (m, 4H, 2 ˆ CH2OP), 3.38–3.35 (m, 1H, HC3), 3.05 (s, 3H,
CH3N), 3.04–2.91 (m, 2H, HαC4, HβC4), 1.41 (t, 3J = 7.2 Hz, 3H, CH3CH2OP), 1.39 (t, 3J = 7.2 Hz, 3H,
CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ = 166.51 (s, C(O)), 162.65, 151.35, 147.82, 143.45, 134.04,
128.90, 128.45, 128.07, 127.48, 123.84, 123.19, 115.29, 80.10 (d, 3J(CCCP) = 8.8 Hz, C5), 67.18 (s, N-CH2),
64.42 (d, 1J(CP) = 168.6 Hz, C3), 63.25 (d, 2J(COP) = 5.3 Hz, CH2OP), 62.46 (d, 2J(COP) = 6.9 Hz, CH2OP),
46.58 (s, CH3N), 37.84 (s, C4), 16.55 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP), 16.50 (d, 3J(CCOP) = 5.7 Hz,
CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.05. Anal. Calcd. for C23H27N4O7P ˆ 0.5 H2O: C,
54.01; H, 5.52; N, 10.95. Found: C, 53.91; H, 5.24; N, 10.95 (obtained on a 90:10 mixture of trans-11e and
cis-11e).
Diethyl trans-(5-(3-(2-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)-phosphonate
(trans-11f). Data noted below correspond to a 90:10 mixture of trans-11f and cis-11f. A colorless oil; IR
(film, cm´1) νmax: 3067, 2981, 2930, 2909, 1620, 1574, 1498, 1457, 1418, 1346, 1298, 1162, 1101, 1025, 965,
770, 682. (signals of trans-11f were extracted from the spectra of a 90:10 mixture of trans-11f and cis-11f);
1H-NMR (600 MHz, CDCl3): δ = 8.17–8.15 (m, 1H), 7.95–7.93 (m, 1H), 7.83–7.80 (m, 1H), 7.58–7.52 (m,
2H), 7.36–7.32 (m, 1H), 7.17–7.15 (m, 1H), 7.13–7.10 (m, 1H), 5.73 (AB, 2JAB = 12.6 Hz, 1H, N-CH2b), 5.70
(AB, 2JAB = 12.6 Hz, 1H, N-CH2a), 5.26 (dd, 3J(H5–H4β) = 7.3 Hz, 3J(H5–H4α) = 6.7 Hz, 1H, HC5), 4.32–4.18
(m, 4H, 2 ˆ CH2OP), 3.43–3.40 (m, 1H, HC3), 3.04 (s, 3H, CH3N), 3.03–2.93 (m, 2H, HαC4, HβC4), 1.40
(t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.38 (t, 3J = 7.1 Hz, 3H, CH3CH2OP). 13C-NMR (151.0 MHz, CDCl3):
δ = 166.86 (s, C(O)), 162.84, 161.08 (d, 1J(CF) = 248.6 Hz, C2’), 151.19, 133.76, 130.60 (d, 3J(CCCF) = 3.4 Hz,
C4’), 130.26 (d, 3J(CCCF) = 8.6 Hz, C6’), 127.85, 127.17, 124.17 (d, 4J(CCCCF) = 3.3 Hz, C5’), 123.45, 123.31
(d, 2J(CCF) = 14.3 Hz, C3’), 115.54 (d, 2J(CCF) = 21.4 Hz, C1’), 115.49, 80.27 (dd, 3J(CCCP) = 8.7 Hz, C5),
64.41 (d, 1J(CP) = 168.3 Hz, C3), 63.23 (d, 2J(COP) = 6.3 Hz, CH2OP), 62.60 (d, 3J = 4.3 Hz, CH2N), 62.39
(d, 2J(COP) = 6.8 Hz, CH2OP), 46.61 (s, CH3N), 37.94 (s, C4), 16.56 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP),
16.50 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.16. Anal. Calcd. for
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C23H27FN3O5P ˆ 0.5 H2O: C, 57.02; H, 5.83; N, 8.67. Found: C, 57.30; H, 5.58; N, 8.62 (obtained on a
90:10 mixture of trans-11f and cis-11f).
Diethyl trans-(5-(3-(3-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)-phosphonate
(trans-11g). Colorless oil; IR (film, cm´1) νmax: 3066, 2982, 2909, 1620, 1575, 1497, 1452, 1416, 1343, 1299,
1163, 1104, 966, 775, 682. 1H-NMR (600 MHz, CDCl3): δ = 8.22–8.20 (m, 1H), 7.98–7.96 (m, 1H), 7.86–7.84
(m, 1H), 7.59–7.57 (m, 1H), 7.40–7.37 (m, 1H), 7.31–7.28 (m, 2H), 7.08–7.06 (m, 1H), 5.66 (s, 2H, N-CH2),
5.27 (dd, 3J(H5–H4β) = 7.4 Hz, 3J(H5–H4α) = 6.7 Hz, 1H, HC5), 4.33–4.21 (m, 4H, 2 ˆ CH2OP), 3.42–3.40
(m,1H, HC3), 3.05 (s, 3H, CH3N), 3.04–2.94 (m, 2H, HαC4, HβC4) 1.42 (t, 3J = 7.1 Hz, 3H, CH3CH2OP),
1.39 (t, 3J = 7.0 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ = 166.80 (s, C(O)), 162.92 (d,
1J(CF) = 246.6 Hz, C3’), 162.80, 151.25, 138.65 (d, 3J(CCCF) = 7.6 Hz, C5’), 133.84, 130.17 (d, J = 8.7 Hz,
C1’), 127.94, 127.27, 123.60 (d, 4J(CCCCF) = 2.6 Hz, C6’), 123.39, 115.47, 115.18 (d, 2J(CCF) = 21.0 Hz, C4’),
115.00 (d, 2J(CCF) = 22.0 Hz, C2’), 80.22 (dd, 3J(CCCP) = 7.9 Hz, C5), 67.80 (d, 3J = 1.6 Hz, CH2N), 64.43 (d,
1J(CP) = 168.3 Hz, C3), 63.26 (d, 2J(COP) = 6.7 Hz, CH2OP), 62.41 (d, 2J(COP) = 6.4 Hz, CH2OP), 46.59 (s,
CH3N), 37.92 (s, C4), 16.56 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP), 16.50 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP).
31P-NMR (243 MHz, CDCl3): δ = 22.14. Anal. Calcd. for C23H27FN3O5P ˆ 0.5 H2O: C, 57.02; H, 5.83;
N, 8.67. Found: C, 57.30; H, 5.66; N, 8.74.
Diethyl trans-(5-(3-(4-fluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)-phosphonate
(trans-11h). Colorless oil; IR (film, cm´1) νmax: 3069, 2982, 2930, 2910, 1620, 1574, 1512, 1498, 1226,
1104, 966, 823, 774, 683. 1H-NMR (600 MHz, CDCl3): δ = 8.17–8.15 (m, 1H), 7.96–7.94 (m, 1H),
7.84–7.81 (m, 1H), 7.56–7.51 (m, 3H), 7.11–7.08 (m, 2H), 5.62 (s, 2H, N-CH2), 5.27 (dd, 3J(H5–H4β)
= 6.7 Hz, 3J(H5–H4α) = 6.7 Hz, 1H, HC5), 4.32–4.20 (m, 4H, 2 ˆ CH2OP), 3.43–3.40 (m, 1H, HC3),
3.07–2.99 (m, 1H, HβC4), 3.06 (s, 3H, CH3N), 2.99 (dddd, 3J(H4α–P) = 12.5 Hz, 2J(H4α–H4β) = 12.5 Hz,
3J(H4α–H3) = 10.3 Hz, 3J(H4α–H5) = 6.7 Hz, 1H, HαC4), 1.41 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.39 (t,
3J = 6.4 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ = 166. 90 (s, C(O)), 162.84, 162.73 (d,
1J(CF) = 246.9 Hz, C4’), 151.21, 133.76, 131.93 (d, 4J(CCCCF) = 3.2 Hz, C1’), 130.28 (d, 3J(CCCF) = 8.0 Hz,
C2’, C6’), 127.89, 127.18, 123.41, 115.53 (d, 2J(CCF) = 21.4 Hz, C3’, C5’), 115.52, 80.23 (d, 3J(CCP) = 8.1 Hz,
C5), 68.02 (s, N-CH2), 64.45 (d, 1J(CP) = 168.1 Hz, C3), 63.25 (d, 2J(COP) = 6.4 Hz, CH2OP), 62.39 (d,
2J(COP) = 6.9 Hz, CH2OP), 46.62 (s, CH3N), 37.96 (s, C4), 16.56 (d, 3J(CCOP) = 5.6 Hz, CH3CH2OP),
16.50 (d, 3J(CCOP) = 5.5 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.13. Anal. Calcd. for
C23H27FN3O5P: C, 58.10; H, 5.72; N, 8.84. Found: C, 57.74; H, 5.70; N, 8.77.
Diethyl trans-(5-(3-(2,4-difluorobenzyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)-
phosphonate (trans-11i). Data noted below correspond to a 92:8 mixture of trans-11i and cis-11i.
A colorless oil; IR (film, cm´1) νmax: 3068, 2982, 2930, 2910, 1621, 1574, 1498, 1416, 1162, 1102, 1025,
961, 773, 682. (signals of trans-11i were extracted from the spectra of a 92:8 mixture of trans-11i
and cis-11i); 1H-NMR (600 MHz, CDCl3): δ = 8.18–8.16 (m, 1H), 7.98–7.96 (m, 1H), 7.86–7.84
(m, 1H), 7.62–7.56 (m, 2H), 6.95–6.89 (m, 2H), 5.71 (AB, 2JAB = 12.4 Hz, 1H, N-CH2b), 5.71 (AB,
2JAB = 12.4 Hz, 1H, N-CH2a), 5.29 (dd, 3J(H5–H4β) = 6.6 Hz, 3J(H5–H4α) = 6.2 Hz, 1H, HC5), 4.34–4.22
(m, 4H, 2 ˆ CH2OP), 3.44–3.41 (m, 1H, C3), 3.07 (s, 3H, CH3-N), 3.04–3.02 (m, 1H, HβC4), 3.01
(dddd, 3J(H4α–P) = 12.4 Hz, 2J(H4α–H4β) = 12.4 Hz, 3J(H4α–H3) = 10.1 Hz, 3J(H4α–H5) = 6.2 Hz, 1H,
HαC4), 1.43 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.41 (t, 3J = 7.0 Hz, 3H, CH3CH2OP). 13C-NMR
(151 MHz, CDCl3): δ = 165.94 (s, C(O)), 163.05 (dd, 1J(CF) = 265.3 Hz, 3J(CCCF) = 12.1 Hz, C2’), 162.71,
161.44 (dd, 1J(CF) = 266.1 Hz, 3J(CCCF) = 14.4 Hz, C4’), 151.19, 133.76, 131.87 (dd, 3J(CCCF) = 9.9 Hz,
3J(CCCF) = 5.5 Hz, C6’), 127.85, 127.18, 123.33, 119.34 (dd, 2J(CCF) = 14.5 Hz, 4J(CCCCF) = 3.3 Hz,
C1’), 115.38, 111.35 (dd, 2J(CCF) = 21.0 Hz, 4J(CCCCF) = 3.3 Hz, C5’), 104.02 (dd, 2J(CCF) = 25.3 Hz,
2J(CCF) = 25.3 Hz, C3’), 80.20 (dd, 3J(CCCP) = 8.7 Hz, 3J(CCCF) = 2.3 Hz, C5), 64.41 (d, 1J(CP) = 168.2 Hz,
C3), 63.19 (d, 2J(COP) = 6.1 Hz, CH2OP), 62.35 (d, 2J(COP) = 7.3 Hz, CH2OP), 62.04 (d, 3J(CCCF) = 3.2 Hz,
CH2N), 46.45 (d, 3J(CNCP) = 2.6 Hz, CH3N), 37.89 (d, 2J(CCP) = 1.7 Hz, C4), 16.52 (d, 3J(CCOP) = 5.5 Hz,
CH3CH2OP), 16.45 (d, 3J(CCOP) = 5.5 Hz, CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.13. Anal.
Calcd. for C23H26F2N3O5P ˆ 0.5 H2O: C, 54.98; H, 5.42; N, 8.36. Found: C, 55.08; H, 5.14; N, 8.26
(obtained on a 92:8 mixture of trans-11i and cis-11i).
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Diethyl trans-(2-methyl-5-(3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)isoxazolidin-3-yl)phosphonate
(trans-11j). Colorless oil; IR (film, cm´1) νmax: 2983, 2955, 2924, 2854, 1679, 1601, 1474, 1435, 1340,
1299, 1241, 1053, 1022, 945, 781, 695, 653, 600, 559. 1H-NMR (600 MHz, CDCl3): δ = 8.28–8.25 (m, 1H),
7.75–7.72 (m, 1H), 7.68–7.66 (m, 1H), 7.50–7.47 (m, 1H), 5.18 (dd, 3J(H5–H4β) = 7.7 Hz, 3J(H5–H4α) = 5.6 Hz,
1H, HC5), 4.30–4.22 (m, 4H, 2 ˆ CH2OP), 3.75 (dddd, 3J(H4α–P) = 14.0 Hz, 2J(H4α–H4β) = 12.7 Hz,
3J(H4α–H3) = 9.1 Hz, 3J(H4α–H5) = 5.6 Hz, 1H, HβC4), 3.74 (s, 3H, CH3N), 3.37 (ddd, 3J(H3–H4α) = 9.1 Hz,
3J(H3–H4β) = 7.7 Hz, 2J(H3-P) = 2.7 Hz, 1H, HC3), 2.79 (dddd, 3J(H4β–P) = 15.4 Hz, 2J(H4β–H4α) = 12.7 Hz,
3J(H4β–H3) = 7.7 Hz, 3J (H4β–H5) = 7.7 Hz, 1H, HβC4), 1.40 (t, 3J = 7.1 Hz, 3H, CH3CH2OP), 1.39 (t,
3J = 7.1 Hz, 3H, CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ = 162.50 (s, C(O)), 152.24, 146.52, 134.08,
127.62, 127.41, 126.79, 120.98, 76.37 (d, 3J(CCCP) = 7.8 Hz, C5), 64.38 (d, 1J(CP) = 170.6 Hz, C3), 63.02
(d, 2J(COP) = 6.6 Hz, CH2OP), 62.70 (d, 2J(COP) = 6.9 Hz, CH2OP), 47.21 (d, 3J(CNCP) = 6.3 Hz, CH3N),
34.41 (s, C4), 30.77 (s, CH3N) 16.56 (d, 3J(CCOP) = 5.0 Hz, CH3CH2OP), 16.53 (d, 3J(CCOP) = 4.9 Hz,
CH3CH2OP). 31P-NMR (243 MHz, CDCl3): δ = 22.09. Anal. Calcd. for C17H24N3O5P ˆ H2O: C, 51.13;
H, 6.56; N, 10.52. Found: C, 51.23; H, 6.17; N, 10.49.
Diethyl trans-(5-(3-ethyl-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylisoxazolidin-3-yl)phosphonate (trans-11k).
Data noted below correspond to a 94:6 mixture of trans-11k and cis-11k. Yellowish oil; IR (film, cm´1)
νmax: 3068, 2981, 2930, 2870, 1620, 1574, 1501, 1424, 1382, 1340, 1240, 1164, 1105, 1053, 1023, 967, 774,
684, 581. (signals of trans-11k were extracted from the spectra of a 94:6 mixture of trans-11k and cis-11k);
1H-NMR (600 MHz, CDCl3): δ = 8.19–8.17 (m, 1H), 7.96–7.94 (m, 1H), 7.84–7.82 (m, 1H), 7.58–7.55 (m,
1H), 5.26 (dd, 3J(H5–H4β) = 7.4 Hz, 3J(H5–H4α) = 6.4 Hz, 1H, HC5), 4.69 (q, 3J = 7.1 Hz, 2H, CH3CH2),
4.34–4.21 (m, 4H, 2 ˆ CH2OP), 3.49–3.46 (m, 1H, HC3), 3.08 (s, 3H, CH3N), 3.10–2.96 (m, 2H, HαC4,
HβC4), 1.55 (t, 3J = 7.1 Hz, 3H, CH3CH2), 1.42 (t, 3J = 7.0 Hz, 3H, CH3CH2OP), 1.39 (t, 3J = 7.1 Hz, 3H,
CH3CH2OP). 13C-NMR (151 MHz, CDCl3): δ =167.25 (s, C(O)), 163.16, 151.03, 133.51, 127.77, 126.92,
123.44, 115.60, 80.36 (d, 3J(CCCP) = 8.3 Hz, C5), 64.38 (d, 1J(CP) = 168.2 Hz, C3), 63.23 (d, 2J(COP) = 6.4 Hz,
CH2OP), 62.36 (d, 2J(COP) = 6.7 Hz, CH2OP), 47.21 (d, 3J(CNCP) = 6.3 Hz, CH3N), 34.41 (s, C4), 29.64 (s,
CH3CH2) 16.53 (d, 3J(CCOP) = 5.7 Hz, CH3CH2OP), 16.47 (d, 3J(CCOP) = 5.8 Hz, CH3CH2OP), 14.29 (s,
CH3CH2). 31P-NMR (243 MHz, CDCl3): δ = 22.23. Anal. Calcd. for C18H26N3O5P: C, 54.68; H, 6.63; N,
10.63. Found: C, 54.93; H, 6.51; N, 10.21 (obtained on a 94:6 mixture of trans-11k and cis-11k).
3.5. Antiviral Activity Assays
The compounds were evaluated against different herpesviruses, including herpes simplex virus
type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK´) HSV-1 KOS strain resistant to ACV
(ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain Oka, TK´
VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis as well as feline herpes
virus (FHV), the poxvirus vaccinia virus (Lederle strain), para-influenza-3 virus, reovirus-1, Sindbis
virus, Coxsackie virus B4, Punta Toro virus, respiratory syncytial virus (RSV), feline coronovirus
(FIPV) and influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza B virus
(B/HK/5/72) and human immune deficiency virus (5HVV-1 and HIV-2). The antiviral assays, other
than HIV, were based on inhibition of virus-induced cytopathicity or plaque formation in human
embryonic lung (HEL) fibroblasts, African green monkey kidney cells (Vero), human epithelial cervix
carcinoma cells (HeLa), Crandell-Rees feline kidney cells (CRFK), or Madin Darby canine kidney cells
(MDCK). Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus
(1 CCID50 being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU)
and the cell cultures were incubated in the presence of varying concentrations of the test compounds.
Viral cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the
control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity
was expressed as the EC50 or compound concentration required to reduce virus-induced cytopathicity
or viral plaque formation by 50%. Cytotoxicity of the test compounds was expressed as the minimum
cytotoxic concentration (MCC) or the compound concentration that caused a microscopically detectable
alteration of cell morphology.
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3.6. Cytostatic Activity against Immortalized Cell Lines
Murine leukemia (L1210), human T-lymphocyte (CEM), human cervix carcinoma (HeLa)
and immortalized human dermal microvascular endothelial cells (HMEC-1) were suspended at
300,000–500,000 cells/mL of culture medium, and 100 µL of a cell suspension was added to 100
µL of an appropriate dilution of the test compounds in 200 µL-wells of 96-well microtiter plates. After
incubation at 37 ˝C for two (L1210), three (CEM) or four (HeLa) days, the cell number was determined
using a Coulter counter. The IC50 was defined as the compound concentration required to inhibit cell
proliferation by 50%.
4. Conclusions
A series of isoxazolidine-containing quinazolinones trans-11 and cis-11 have been
synthesised from N-methyl-C-diethoxyphosphorylnitrone (12) and the respective N3-substituted
2-vinyl-quinazolin-ones 13 via the 1,3-dipolar cycloaddition. The obtained isoxazolidine phosphonates
trans-11 or the respective mixtures of trans-11/cis-11 were evaluated against a variety of DNA and
RNA viruses. Among all tested compounds, isoxazolidines trans-11f/cis-11f (90:10), trans-11h and
trans-11i/cis-11i were slightly active toward TK+VZV strain (EC50 = 6.84, 15.29 and 9.44 µM) without
exhibiting cytotoxicity toward uninfected cells at concentration up to 100 µM. On the other hand,
phosphonates trans-11b/cis-11b (90:10), trans-11c, trans-11e/cis-11e (90:10) and trans-11g showed weak
antiviral properties against cytomegalovirus (EC50 = 27–45 µM).
Compounds equipped with benzyl substituents at N3 in the quinazolinone skeleton exhibited
some antiproliferative activity toward the tested immortalized cells (IC50 = 21–102 µM), while
analogues lacking substituent or having alkyl group at N3 were inactive. These results encourage
us to continue the search for more active compounds with special focus on modification the
quinazoline-4-one unit especially at N3.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/7/959/s1.
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